Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer

NCT ID: NCT02342587

Last Updated: 2017-02-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-03
• Study Completion Date: 2016-08-21

Brief Summary

Although anti-HER2 (human epidermal growth factor receptor 2) therapy is currently approved for breast, gastric, and gastroesophageal cancers overexpressing the HER2 protein or amplified for the HER2 gene, HER2 aberrations (gene amplification, gene mutations, and protein overexpression) are reported in other diverse malignancies. Indeed, about 1-37% of tumors of the following types harbor HER2 aberrations: bladder, cervix, colon, endometrium, germ cell, glioblastoma, head and neck, liver, lung, ovarian, pancreas, and salivary duct.

Lapatinib is an orally active, reversible, small molecule TKI that potently inhibits both ErbB1 and ErbB2 tyrosine kinase activity. Data suggest that a dual ErbB1 and ErbB2 inhibitor may provide improved therapeutic benefit compared with inhibitors that target only one or the other receptor.

Therefore, this phase 2 study is designed to evaluated the activity of lapatinib in patients with HER2-positive refractory cancer.

Conditions

HER2-positive Refractory Advanced Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

single arm

Patients will be treated with oral lapatinib 1250mg once daily for 21 days.

Group Type: EXPERIMENTAL

Lapatinib

Intervention Type: DRUG

Patients will be treated with oral lapatinib 1250mg once daily for 21 days.

Interventions

Lapatinib

Patients will be treated with oral lapatinib 1250mg once daily for 21 days.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age > 19
• Written informed consent
• ECOG 0-2,
• Histologically confirmed HER2-positive Refractory solid tumor(IHC 3+ alone, or IHC 2+ with FISH amplification) and/or specific sensitivity to Lapatinib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy.
• The presence of measurable disease as defined by the Response (Evaluation Criteria in Solid Tumors (RECIST) version 1.1)
• Adequate organ function

Exclusion Criteria

• Uncontrolled symptomatic brain metastasis,Uncontrolled active infection
• Uncontrolled systemic illness (DM, CHF, unstable angina, hypertension or arrhythmia)
• Prolonged QT interval in ECG (QTc >450 msec)
• Pregnant, lactating women
• Prior treatment with lapatinib,Malabsorption syndrome, any disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, or persons unable to swallow oral medication
• Prior history of malignancy within 5 years from study entry except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer, well-treated thyroid cancer

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Samsung Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Jeeyun Lee

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Samsung Medical Center

Seoul, , South Korea

Countries

South Korea

Other Identifiers

2014-10-028

Identifier Type: -

Identifier Source: org_study_id